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1. Introduction 
The methods used for treating stage Ib2-IIb cervical cancers, with a bulky mass, differ between 
Japan and Western countries. In Western countries, concurrent chemoradiation (CCRT) has 
been recommended as a standard therapy for such tumors based on the results of multiple 
large-scale randomized trials and meta-analyses (Morris et al., 1999; Rose et al., 1999; Whitney 
et al., 1999; Pearcey et al., 2002; Eifel et al. 2004; Green et al. 2001; Lukka et al., 2002). In Japan, 
Korea, Italy and some other countries, the neoadjuvant chemotherapy (NAC) approach has 
been extensively introduced to clinical practice (Sugiyama et al., 1999). NAC is considered to 
be clinically significant in 2 respects: it is expected to improve the radicality and safety of 
surgery by reducing tumor size; and it is expected to exert systemic effects, i.e., effects on 
lymph node occult micrometastases, etc. A disadvantage of NAC is delayed initiation of the 
primary treatment, suggesting the necessity of completing NAC as an auxiliary therapy within 
a short period of time. Therefore, we may find that NAC is valuable if it can exert efficacy 
rapidly with high platinum dose intensity (DI), assuring that subsequent primary surgical 
therapy can be performed as soon as possible. At our facility, a platinum-based regimen has 
been used for NAC in patients with cervical cancer. Herein, we review the efficacy and safety 
data on NAC for squamous cell carcinoma of the uterine cervix. We previously reported our 
interim data and now present the results of an ongoing pilot study on the efficacy and safety of 
NAC for non-squamous cell carcinoma of the uterine cervix.  
2. Subjects and methods 
2.1 Subjects 
We studied 43 patients with locally advanced cancer of the uterine cervix (clinical stage Ib2 
to IIb) who gave informed consent to participate in this study between January 2002 and 
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September 2010. All 43 were scheduled to undergo a radical hysterectomy, including 23 
with squamous cell carcinoma and 20 with non-squamous cell carcinoma.  
2.2 Inclusion criteria 
The following set of inclusion criteria was employed for selection of study subjects. (1) 
Histologically verified squamous cell carcinoma or non-squamous cell carcinoma of the 
uterine cervix; (2) locally advanced stage Ib2 to IIb; (3) age: 20 years upward and less than 70 
years; (4) Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-2; (5) 
initially treated case; (6) the presence of an MRI-measurable bulky mass in the uterine 
cervix; (7) hematologic and blood biochemical findings meeting the following criteria [WBC 
count  4,000/mm3 ; neutrophil count   2,000/mm3 ; platelet count  100,000/mm3 ; 
hemoglobin 10.0 g/dl ; AST and ALT levels  2 times the upper limit of normal reference 
range at study site ; serum total bilirubin level 1.5 mg/dl ; serum creatinine 1.5 mg/dl ; 
and creatinine clearance 60 ml/min]; (8)life expectancy 6 months; and (9) written 
informed consent personally given by the subject. 
2.3 Exclusion criteria 
Exclusion criteria were prescribed as follows. (1) Patients with overt infection; (2) patients 
with a serious complication(s) (e.g., cardiac disease, poorly controlled diabetes mellitus, 
malignant hypertension, bleeding tendency); (3) patients with active multiple cancer; (4) 
patients with interstitial pneumonia or pulmonary fibrosis; (5) patients with effusions; (6) 
patients with a history of unstable angina or myocardial infarction within 6 months after 
registration, or with a concurrent serious arrhythmia requiring treatment; (7) patients in 
whom treatment with cisplatin (CDDP), irinotecan (CPT-11), paclitaxel (PTX), docetaxel 
(DTX) and carboplatin (CBDCA) is contraindicated; (8) patients with (watery) diarrhea; (9) 
patients with intestinal paralysis or ileus; (10) pregnant women, nursing mothers or women 
wishing to become pregnant; (11) patients with a history of serious drug hypersensitivity or 
drug allergy; and (12) patients who were inadequate for safe conduct of this study as judged 
by the attending physician. 
2.4 Administration method and criteria for modification 
2.4.1 NAC for squamous cell carcinoma 
One course of NAC consisted of 21 days, with a CDDP dose of 70 mg/m2 on Day 1 and 
intravenous CPT-11 doses of 70 mg/m2 on Days 1 and 8. As a rule, 2 courses of NAC were 
administered to each patient (Fig.1). 
2.4.1.1 Criteria for skipping CPT-11 
In cases in which hematological data within 2 days before Day 8 did not satisfy the 
following criteria, CPT-11 was skipped on Day 8: 1) neutrophil count  1,000/mm3, 2) 
platelet count  75,000/mm3. 
2.4.1.2 Criteria for starting the next course of NAC 
In cases in which hematological data within 2 days before the planned start of the next 
course of treatment did not satisfy the following criteria, starting the second course was 
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postponed by 2 weeks at a maximum: 1) neutrophil count  1,500/mm3, 2) platelet count  
75,000/mm3, 3) serum creatinine  1.5 mg/dl. 
 
Fig. 1. Treatment protocol of NAC for cervical cancer 
2.4.1.3 Dose reduction criteria 
In cases exhibiting the following signs of toxicity during the first course of treatment, the 
CPT-11 and CDDP doses for the second course were reduced from 70 mg/m2 to 60 
mg/m2: Grade 4 neutropenia lasting 7 days or more; febrile neutropenia lasting 4 days or 
more; Grade 4 thrombocytopenia; Grade 3 thrombocytopenia accompanied by bleeding; 
and Grade 3 or more severe non-hematological signs of toxicity other than nausea and 
vomiting.  
2.4.2 NAC for non-squamous cell carcinoma 
One course of treatment was 21 days, with a PTX dose of 175 mg/m2 or DTX dose of 70 
mg/m2 on Day 1 and intravenous CBDCA AUC 6 on Day 1. As a rule, 2 courses of 
treatment were administered to each patient (Fig.1) . 
2.4.2.1 Criteria for starting the next course of treatment 
In cases in which hematological data within 2 days before the planned start of the second 
course of treatment did not satisfy the following criteria, starting the second course was 
postponed by 2 weeks at a maximum: 1) neutrophil count  1,000/mm3, 2) platelet count  
75,000/mm3. 
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2.4.2.2 CBDCA dose reduction criteria 
In cases exhibiting the following signs of toxicity during the first course of treatment, the 
CBDCA dose for the second course was reduced from AUC 6 to 5. If signs of toxicity 
remained after this dose reduction, that for the third course of treatment was reduced from 
AUC 5 to 4: Grade 4 thrombocytopenia; and Grade 3 thrombocytopenia accompanied by 
bleeding.  
2.4.2.3 PTX dose reduction criteria 
In cases exhibiting signs of Grade 2 or more severe peripheral nerve toxicity during the first 
course, the PTX dose for the second course was reduced from 175 mg/m2 to 135 mg/m2. If 
Grade 2 or more severe peripheral nerve toxicity remained after dose reduction, the PTX 
dose for the third course was reduced from 135 mg/m2 to 110 mg/m2. 
2.4.2.4 DTX dose reduction criteria 
In cases exhibiting the following signs of toxicity during the first course, the DTX dose for 
the second course was reduced from 70 mg/m2 to 60 mg/m2. If signs of toxicity remained 
after this dose reduction, the DTX dose for the third course was reduced from 60 mg/m2 to 
50 mg/m2: Grade 4 neutropenia lasting 7 days or more; and febrile neutropenia lasting 4 
days or more. 
2.5 Supportive therapy 
A granulocyte-colony stimulating factor (G-CSF) preparation was administered in patients 
developing Grade 4 neutropenia during the first course of NAC. Administration of the G-
CSF preparation was permitted for prophylactic purposes during the second and 
subsequent courses of NAC in cases exhibiting Grade 4 neutropenia during the first course. 
Anti-emetics were additionally used for prophylactic purposes.  
2.6 Observations and tests 
The primary endpoint was anti-tumor response. Secondary endpoints were adverse events, 
surgery completion rate, progression-free survival period, and overall survival period. 
Hematological tests and urinalysis were carried out before the start of treatment and once 
weekly, as a rule, after starting treatment. Electrocardiograms and chest X-rays were 
obtained before the start and at the end of treatment.  
2.6.1 Evaluation of anti-tumor response 
Anti-tumor response was evaluated using Response Evaluation Criteria in Solid Tumors 
(RECIST) by comparing the baseline findings (before the start of treatment) on magnetic 
resonance imaging (MRI) with the MRI findings at the end of treatment courses. Efficacy 
evaluation adopted the best rating, without incorporating the response period.  
2.6.2 Evaluation of adverse events  
Adverse events were evaluated employing the National Cancer Institute Common Toxicity 
Criteria (NCI-CTCAE) version 3.0. 
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2.7 Primary treatment 
Patients with stage Ib2-IIb carcinoma underwent a radical hysterectomy unless the response 
of the tumor to preoperative treatment was progressive disease (PD) and the tumor was up-
staged. In cases in which surgery was not possible, concurrent CCRT was adopted. 
2.8 Postoperative therapy 
Postoperative radiotherapy or chemotherapy was undertaken additionally in patients with 
positive vaginal stump, positive lymphadenopathy, positive invasion of the cardinal 
ligament, or evident invasion of the vasculature. 
3. Results 
3.1. Results of NAC for squamous cell carcinoma 
3.1.1 Background variables 
The median age of the 23 patients was 40 (range: 25-63) years. PS was 0 in 20 cases (87.0%) 
and 1 in 3 (13.0%). The clinical stage of the tumor was Ib5 in 5 cases (21.7%), IIa in 2 (8.7%), 
and IIb in 16 (69.6%). All patients received 2 courses of NAC (Table 1). 
 
Table 1. Patient characteristics 
3.1.2 Anti-tumor response 
The response of the tumor to treatment was assessed in all cases. Five (21.7%) showed a 
complete response (CR), 15 (65.2%) a partial response (PR), 2 (8.7%) stable disease (SD), and 
1 (4.3%) PD. Thus, the response rate was 87.0% (Table 2). Among the cases rated as showing 
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CR or PR, none showed tumor growth between the end of the first course and the end of the 
second course of treatment. 
 
Table 2. Response and clinical outcome 
3.1.3 Adverse events 
Grade 3 or more severe leukopenia and neutropenia were seen in 6 cases (26.1%) and 14 
cases (60.9%), respectively. Grade 3 febrile neutropenia was seen in 1 case (4.3%). The G-CSF 
preparation was used in 11 (55.0%) of the 23 cases; during 17 (42.5%) of the 46 treatment 
cycles in total. The mean duration of G-CSF treatment during each course was 3.1 days. 
Grade 3 or more severe anemia was noted in 3 cases (15.0%), including one patient with 
Grade 1 anemia requiring blood transfusion. None of the patients developed Grade 3 or 
more severe thrombocytopenia. Signs of Grade 3 or more severe non-hematological toxicity 
included nausea in 2 cases (8.7%) and vomiting in 1 (4.3%) (Table 3). No treatment-
associated deaths occurred. Chemotherapy was completed as scheduled in 21 (91.3%) of the 
23 cases. In the remaining 2 cases, the CPT-11 dose on Day 2 of the second course was 
skipped. In these 2 cases, the dose was skipped at the discretion of the attending physician 
because of persistent Grade 3 nausea. There were 2 cases (8.7%) in which the start of the 
second course was postponed because the neutrophil count criterion was not satisfied. In 
both cases, the second course was started within 7 days. In one case (4.3%) showing febrile 
neutropenia lasting at least 4 days, the CDDP and CPT-11 doses for the second course were 
reduced from 70 mg/m2 to 60 mg/m2. 
3.1.4 Surgery completion rate and survival period 
The completion rate of radical hysterectomy after NAC was 100%. The median follow-up 
period was 35 months (range: 8-93 months). The median progression-free survival period 
was 30 months (8-93 months). The median overall survival period was 34 months (8-93 
months) (Table 2). 
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Table 3. Toxicity of CPT-11+CDDP therapy (n=23) 
3.2 Results of NAC for non-squamous cell carcinoma 
3.2.1 Background variables 
The median age of the 20 patients was 51 (range: 30-63) years. PS was 0 in 15 cases (75.0%) 
and 1 in 5 (15.0%). The clinical stage was Ib2 in 5 cases (25.0%) and IIb in 15 (75.0%). The 
histological type was mucinous adenocarcinoma in 9 cases (45.0%), endometrioid 
adenocarcinoma in 3 (15.0%), clear cell adenocarcinoma in 1 (5.0%), and adenosquamous 
carcinoma in 7 (35.0%). One course of NAC was administered to 1 case (5.0%), 2 courses to 
16 (80.0%), and 3 courses to 3 (15.0%) (Table 1). 
3.2.2 Anti-tumor response 
The response was rated as CR in 4 cases (20.0%), PR in 11 (55.0%), SD in 5 (10.0%), and PD in 
1 (4.3%), with the response rate being 75.0% (Table 2). 
3.2.3 Adverse events 
Grade 3 or more severe leukopenia and neutropenia were seen in 10 (50.0%) and 19 (95.0%) 
cases, respectively. Grade 3 febrile neutropenia was noted in 2 cases (10.0%). The G-CSF 
preparation was used for 13 (65.0%) of the 20 cases; it was administered during 19 (45.2%) of 
the 42 cycles in total. The mean duration of G-CSF preparation treatment during each course 
was 3.0 days. None of the cases showed Grade 3 or more severe anemia or 
thrombocytopenia. The only sign of Grade 3 or more severe non-hematological toxicity was 
nausea, seen in one case (5.0%). None of the cases had signs of Grade 2 or more severe 
neurotoxicity (Table 4). 
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In 3 cases (15.0%), the start of the second course of treatment was postponed because the 
neutrophil count criterion was not satisfied. In all 3 of these cases, the second course was 
started within 7 days. Both cases (10.0%) with Grade 3 febrile neutropenia for 4 days or 
more had received DTX/CBDCA therapy prior to the development of neutropenia. In these 
2 cases, DTX (from 70 mg/m2 to 60 mg/m2) and CBDCA (from AUC 6 to 5) doses were 
reduced for the second course of treatment. 
3.2.4 Surgery completion rate and survival period 
A radical hysterectomy after NAC was completed in 15 of the 20 cases, i.e., the surgery 
completion rate was 75.0%. The median follow-up period was 20 months (6-70 months). The 
median progression-free survival period was 10.5 months (3-70 months) and the median 
overall survival period was 20 months (6-70 months) (Table2). 
 
Table 4. Toxicity of TC or DC therapy (n=20) 
4. Discussion 
A meta-analysis of the results of NAC for squamous cell carcinoma of the uterine cervix 
ruled out the effectiveness of radiotherapy applied as the primary treatment but suggested 
the effectiveness of surgery employed as primary therapy. This analysis suggested the 
effectiveness of NAC, if: one cycle of treatment lasted no more than 14 days; and the DI of 
CDDP exceeded 25 mg/m2/week (Neoadjuvant Chemotherapy for Cervical Cancer Meta-
analysis Collaboration., 2003). Sugiyama et al reported a CDDP/CPT-11 therapy schedule 
involving CPT-11 doses on Days 1, 8, and 15 (one course = 28 days) (Sugiyama et al., 1999). 
We evaluated the efficacy and safety of CDDP/CPT-11 therapy, reportedly an effective 
NAC regimen, using modified doses and administration schedules. In our study, a single 
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dose was set at 70 mg/m2 for both CDDP and CPT-11, and the therapy was administered for 
2 cycles at an interval of 3 weeks, with CDDP administered on Day 1 and CPT-11 on Days 1 
and 8. In this way, the DI of CDDP was raised to 23.3 mg/m2/week, and this schedule was 
expected to reduce the need to skip treatments. Thus, it seems valuable to be able to reduce 
the time interval from NAC to surgery.  
In an analysis of adverse events, Grade 3 or more severe neutropenia developed in 14 
(60.9%) of the 23 cases, but subsided in response to short-term treatment with a G-CSF 
preparation. Severe diarrhea, specific to CPT-11, was not seen in any case when this agent 
was administered at a dose of 70 mg/m2, suggesting that the quality of life (QOL) of 
patients was maintained during this therapy. The first course of treatment was administered 
as scheduled in all cases. The start of the second course was delayed, by no more than 7 
days, in 3 cases. Furthermore, the CPT-11 dose on Day 8 was skipped in 2 cases. Dose 
reduction during the second course was necessary in only 2 cases, suggesting that this 
regimen does not increase the toxicity of these drugs as compared to the dosing regimen 
with 4-week intervals. Furthermore, the response rate (87.6%) and the surgery completion 
rate (100%) were satisfactory. Regarding the outcomes of patients treated with this regimen, 
further follow-up is needed. 
Non-squamous cell carcinoma of the uterine cervix has been steadily rising in Japan, 
currently accounting for approximately 10% to 15% of all cervical cancer cases. Lymph node 
metastasis is more frequent in cases with invasive non-squamous cell carcinoma than in 
those with invasive squamous cell carcinoma (Aoki et al., 2002) and sensitivities to 
radiotherapy and chemotherapy are considered to be lower with non-squamous cell 
carcinoma (Landoni et al., 1997). Thus, squamous and non-squamous cell carcinomas must 
be analyzed separately. It is advisable to try new therapeutic strategies for non-squamous 
cell carcinoma, but the number of published studies involving cases with this type of 
cervical cancer is small, and the number of cases analyzed is also small. Thus, no high-level 
evidence has been obtained for this type of cervical cancer. The response rates of 
adenocarcinoma are reportedly 20% (Thigpen et al., 1986), 15% (Sutton et al., 1993), 14% 
(Look et al., 1997), and 12% (Rose et al., 2003) to uncombined therapies with CDDP,  
ifosmide, 5-FU, and oral etoposide, respectively, indicating that the response rates of 
adenocarcinoma to these therapies tend to be lower than those of squamous cell carcinoma. 
However, according to the report by Curtin et al, the response rate of adenocarcinoma was 
as high as 31% even when PTX was used independently (Curtin et al., 2001). DTX has also 
been attracting considerable interest. Nagao et al evaluated the efficacy of combined 
chemotherapy using DTX + CBDCA (DTX 60 mg/m2 on Day 1, CBDCA AUC 6 on day 1 
and then every 21 days) in 17 patients with advanced/recurrent cervical cancer, including 6 
with adenocarcinoma and 1 with adenosquamous carcinoma, reporting that a PR was 
obtained in 6 of the 7 cases with adenocarcinoma (including the one with adenosquamous 
carcinoma) and that the response rate was thus 86% (Nagao et al., 2005). Following these 
findings, we conducted a pilot study involving standard regimens of PTX/CBDCA and 
DTX/CBDCA conventionally used for the treatment of ovarian cancer.  
In the analysis of adverse events, Grade 3 or more severe neutropenia developed in 19 
(95.0%) of the 20 cases, but subsided in response to short-term treatment with a G-CSF 
preparation (mean dosing period: 3.0 days/course). During the first course of DTX/CBDCA 
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therapy, Grade 3 febrile neutropenia developed in 2 cases. In these 2 cases, the dose was 
reduced during the next course of treatment (DTX, from 70 mg/m2 to 60 mg/m2; CBDCA, 
from AUC 6 to 5). All signs of peripheral neuropathy specific to taxanes, observed during 
this study, were Grade 1 or less severe, allowing continuation of treatment while preserving 
the QOL of individual patients. No serious adverse events occurred, and the response rate 
was 75%, but the completion rate of surgery (radical hysterectomy) was 75%. Thus, the 
outcomes of treatment in this study were not satisfactory. Possible reasons are: rapid 
progression of non-squamous cell carcinoma, frequent invasion of tissues/organs 
surrounding the uterus, and frequent lymph node metastasis.  
Numerous reports on phase II studies of NAC for cervical cancer have been published, 
demonstrating effectiveness in 70%-80% of all cases. Table 5 shows the results of the present 
study in comparison to those of previous reports (Sugiyama et al., 1999; Hwang et al., 2001; 
Dueñas-Gonzalez et al., 2001; D’Agostino et al., 2002; Di Vagno et al., 2003; Dueñas-
Gonzalez et al., 2003; Umesaki et al., 2004; Shoji et al., 2010; Shoji et al., 2010) and this study.  
 
Table 5. Phase II study of NAC for cervical cancer 
Most of the reports shown pertain to evaluation of both squamous cell carcinoma and non-
squamous cell carcinoma. There is an urgent need to conduct clinical studies on each 
histological type of cervical cancer and to establish new methods of treatment specific to 
each type. Only a limited number of reports have demonstrated a high response rate to 
correlate with a better outcome. Thus, randomized controlled trials (RCT) designed to assess 
improvement of long-term outcomes are essential. As an RCT evaluating outcomes after 
NAC, Sardi et al reported a study involving comparisons among 4 groups (NAC + surgery 
+ radiotherapy, surgery + radiotherapy, uncombined radiotherapy, NAC + radiotherapy). 
They found that the survival rate improved significantly with NAC + surgery + 
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radiotherapy (7-year survival rate: 41%) as compared to surgery + radiotherapy (41%) (Sardi 
et al., 1997). Serur et al retrospectively compared the outcomes of treating stage Ib cases 
between a NAC + surgery group and a surgery alone group, demonstrating a higher 5-year 
survival rate in the NAC + surgery group although the difference was not statistically 
significant (80% vs 69%) (Serur et al., 1997). Tierney et al reported the results of a meta-
analysis, stating that there was no prognostic improvement (Neoadjuvant Chemotherapy 
for Cervical Cancer Metaanalysis Colloaboration, 2003). Thus, there is no consensus on this 
issue. 
The JCOG0102 was a representative randomized study of NAC conducted in Japan, 
designed as an RCT comparing the outcomes of treatment for stage Ib2-IIb cases with bulky 
tumors between radical hysterectomy (+RT) and NAC + radical hysterectomy (+RT). The 
JCOG0102 used bleomycin/vincristine/mitomycinC/cisplatin (BOMP) as the NAC 
regimen. In that study, the response rate to BOMP therapy was low as 61%, and the interim 
results did not endorse the usefulness of this therapy, forcing the study to be discontinued 
prematurely (Katsumata et al., 2006). The JGOG1065 was a phase II clinical study on NAC + 
radical hysterectomy, using nedaplatin and CPT-11 for NAC, carried out in 66 patients with 
stage Ib2-IIb cervical cancer with a bulky tumor. In that study, the response rate was 75.8% 
and the 2-year recurrence-free survival period was 73.8% (Shoji et al., 2010). This therapy is 
expected to reduce nephrotoxicity and adverse events such as nausea and vomiting and 
appears to be a useful regimen for patients with renal dysfunction and elderly patients from 
the viewpoint of QOL. However, the response rate to this therapy has not exceeded that to 
CDDP + CPT-11. At present, there is no plan to launch a phase III clinical study on NAC 
(NDP/CPT-11) + radical hysterectomy vs. CCRT. There is no evidence supporting the view 
that NAC improves the outcomes of patients with cervical cancer, and NAC has not been 
recommended in any set of guidelines. Further studies on the indications for and efficacy of 
NAC are clearly needed.  
5. Conclusions 
Irinotecan/cisplatin therapy for squamous carcinoma of the uterine cervix and PTX/ 
CBDCA and DTX/CBDCA therapies for non-squamous cell carcinoma of the uterine cervix 
showed high anti-tumor efficacy, and the adverse reactions to these therapies could be dealt 
with satisfactorily, thus allowing safe treatment. In cases with squamous cell carcinoma, 
outcomes are expected to be improved by NAC, but further evaluation of the outcomes of 
patients with non-squamous cell carcinoma is awaited.  
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